Pilot Program for Center for Devices and Radiological Health Electronic Submission for Home Use Device Labeling, 21743-21744 [2015-08957]

Download as PDF Federal Register / Vol. 80, No. 75 / Monday, April 20, 2015 / Notices by expert panels to be of high quality and to advance the field. • The average number of publications per award based on NIDILRR-funded research and development activities in refereed journals. • The percentage of new NIDILRR grants that assess the effectiveness of interventions, programs, and devices using rigorous methods. NIDILRR uses information submitted by grantees as part of their Annual Performance Reports for these reviews. 5. Continuation Awards: In making a continuation award, the Administrator of the Administration for Community Living may consider, under 45 CFR part 75, the extent to which a grantee has made ‘‘substantial progress toward meeting the objectives in its approved application.’’ This consideration includes the review of a grantee’s progress in meeting the targets and projected outcomes in its approved application, and whether the grantee has expended funds in a manner that is consistent with its approved application and budget. In making a continuation grant, the Administrator also considers whether the grantee is operating in compliance with the assurances in its approved application, including those applicable to Federal civil rights laws that prohibit discrimination in programs or activities receiving Federal financial assistance from the Department. Continuation funding is also subject to availability of funds. VII. Agency Contact FOR FURTHER INFORMATION CONTACT: mstockstill on DSK4VPTVN1PROD with NOTICES Patricia Barrett, U.S. Department of Health and Human Services, 400 Maryland Avenue SW., room 5142, PCP, Washington, DC 20202–2700. Telephone: (202) 245–6211 or by email: patricia.barrett@acl.hhs.gov. If you use a TDD or a TTY, call the Federal Relay Service (FRS), toll free, at 1–800–877–8339. VIII. Other Information Electronic Access to This Document: The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available via the Federal Digital System at: www.gpo.gov/fdsys. At this site you can view this document, as well as all other documents of this Department published in the Federal Register, in text or Adobe Portable Document Format (PDF). To use PDF you must have Adobe Acrobat Reader, which is available free at the site. You may also access documents of the Department published in the Federal VerDate Sep<11>2014 17:56 Apr 17, 2015 Jkt 235001 Register by using the article search feature at: www.federalregister.gov. Specifically, through the advanced search feature at this site, you can limit your search to documents published by the Department. Dated: April 14, 2015. John Tschida, Director, National Institute on Disability, Independent Living, and Rehabilitation Research. [FR Doc. 2015–09013 Filed 4–17–15; 8:45 am] BILLING CODE 4154–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2015–N–1037] Pilot Program for Center for Devices and Radiological Health Electronic Submission for Home Use Device Labeling AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) is announcing the availability of a CDRH electronic submissions Pilot Program database to house labeling for home use devices. Participation in the pilot is open to applicants who label their device(s) for home use. Participation in the pilot project is voluntary. Participants will be asked to navigate through the electronic submissions system and practice submitting labels and package inserts. The pilot project is intended to provide industry and CDRH staff the opportunity to evaluate the submissions process and system and to receive comments from industry participants. DATES: FDA will accept applications for participation in the voluntary electronic submissions CDRH Home Use Device Labeling Pilot Program from May 1, 2015, through May 31, 2015. See the ‘‘Participation’’ section for instructions on how to submit a request to participate. The pilot project will occur July 1, 2015, through December 31, 2015. SUMMARY: FOR FURTHER INFORMATION CONTACT: Mary Weick-Brady, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66 Rm. 5426, Silver Spring MD 20993, 301–796–6089, Mary.Brady@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 21743 I. Background CDRH is responsible for ensuring that medical devices are safe and effective when used for their intended purpose. Risks are inherent in all CDRH-regulated medical devices, and the Center plays a critical role in preventing injuries and deaths related to product use. CDRH minimizes risk through regulation, enforcement, and education. Risk minimization is accomplished, in part, through clear communication on the benefits and risks of the medical devices regulated by the Center, including communications by CDRH, product manufacturers, and product distributors. These communications include medical device labeling produced by manufacturers and distributors. Medical device labeling provides safety information, instructions for use, and/or other necessary information to the user. This labeling can be essential for home-use devices, which are much more likely to be used by lay users, who frequently have not been trained to use such medical devices and who are especially reliant on the instructions for use and other information provided by the device label and package insert. When used in an environment where a healthcare professional is not available to provide supervision and assistance, these devices can present unique concerns and challenges. When a homeuse device is used over a period of years, it becomes increasingly more likely that it may be separated from its original labeling or that its original labeling will not include current safety information or instructions for use. In contrast with use in professional healthcare settings, a patient or caregiver using a home-use device in a setting without professional oversight may not have extensive experience in the use of a device and may not have ready access to the original packaging or to alternative sources of information about a device. Home-use devices have significant public health importance to patients, caregivers, and healthcare professionals. Therefore, it is necessary to ensure that users are able to access necessary information for use, including safety information and instructions for use. Although many manufacturers have Internet sites that provide information concerning the devices they currently market, those sites typically focus on newer products and often do not provide any information on devices that they no longer actively market. Web sites also vary considerably in the types of information provided and may lack important details concerning their devices. Although some manufacturers’ E:\FR\FM\20APN1.SGM 20APN1 21744 Federal Register / Vol. 80, No. 75 / Monday, April 20, 2015 / Notices Web sites provide some labeling, FDA believes that most do not provide the label and package insert for all of their home-use devices listed with FDA. II. CDRH Home Use Device Labeling Pilot CDRH is developing an electronic submissions database, accessible to the public through FDA’s Web site, of labels and package inserts for listed home-use devices. This database would fill an important gap in the information available to patients, caregivers, and the healthcare community concerning home-use devices. The database would allow both broad searches to identify legally marketed home-use devices that may fill a particular need and focused searches to obtain information concerning the use of a specific homeuse device. This electronic submissions database will be evaluated for usability through the CDRH Home Use Device Labeling Pilot Project. This pilot project will proceed for 6 months. Participation in the pilot is open to applicants who label their device(s) for home use. Participants will be asked to navigate through the electronic submissions system and practice submitting labels and package inserts. The pilot project is intended to provide industry and CDRH staff the opportunity to evaluate the submissions process and system and to receive comments from industry participants. Comments received during the pilot project will be used to evaluate the usability of the database. FDA will not review the content of any labeling submitted to the pilot database for a regulatory purpose. The submitted labeling and the database will only be available to pilot participants. mstockstill on DSK4VPTVN1PROD with NOTICES A. Participation Volunteers interested in participating in the pilot project should contact pilot staff by email at Mary.Brady@ fda.hhs.gov. The following information should be included in the request: Contact name, contact phone number, and contact email address. FDA will contact interested applicants to discuss the pilot project. FDA is seeking a limited number of participants (no more than nine) to participate in this pilot project. B. Procedures By following a series of prompts and instructions, pilot participants will submit a PDF version of their device labeling to the pilot database. The content of the submissions will not be reviewed by FDA for any regulatory purpose, nor will the pilot database be available to the public during this pilot VerDate Sep<11>2014 17:56 Apr 17, 2015 Jkt 235001 project. During the pilot, CDRH staff will be available to answer any questions or concerns that may arise. Pilot project participants will be asked to comment on and discuss their experiences with the pilot submissions process. Their comments and discussions will assist CDRH in its development of this electronic submissions database. III. Duration of the Home Use Device Labeling Pilot FDA intends to accept requests for participation in the Home Use Device Labeling Pilot from May 1, 2015, through May 31, 2015. The pilot will proceed for 6 months, from July 1, 2015, through December 31, 2015. This pilot program may be extended as resources and needs allow. IV. Paperwork Reduction Act of 1995 This notice refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501– 3520). The collections of information in 21 CFR parts 801 and 809 have been approved under OMB control number 0910–0485. V. Comments Interested persons may submit electronic comments regarding the Home Use Device Labeling Pilot to https://www.regulations.gov or written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday and will be posted to the docket at https:// www.regulations.gov. Dated: April 14, 2015. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2015–08957 Filed 4–17–15; 8:45 am] BILLING CODE 4164–01–P PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary [Document Identifier: HHS–OS–0990–0392– 30–D] Agency Information Collection Activities; Submission to OMB for Review and Approval; Public Comment Request Office of the Secretary, HHS. Notice. AGENCY: ACTION: In compliance with section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, has submitted an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB) for review and approval. The ICR is for renewal of the approved information collection assigned OMB control number 0990–0392, scheduled to expire on May 31, 2015. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public on this ICR during the review and approval period. DATES: Comments on the ICR must be received on or before May 20, 2015. ADDRESSES: Submit your comments to OIRA_submission@omb.eop.gov or via facsimile to (202) 395–5806. FOR FURTHER INFORMATION CONTACT: Information Collection Clearance staff, Information.CollectionClearance@ hhs.gov or (202) 690–6162. SUPPLEMENTARY INFORMATION: When submitting comments or requesting information, please include the OMB control number 0990–0392 and document identifier HHS–OS0990– 0392–30D for reference. Information Collection Request Title: Office of Adolescent Health and Administration for Children, Youth and Families Teen Pregnancy Prevention Performance Measure Collection. Abstract: The Office of Adolescent Health (OAH), U.S. Department of Health and Human Services (HHS) is requesting an extension without change of a currently approved information collection request by OMB. The purpose of the extension is to complete the ongoing data collection for the Office of Adolescent Health and Administration for Children, Youth and Families Teen Pregnancy Prevention Performance Measures. Need and Proposed Use of the Information: To collect performance measure data on the OAH Teen SUMMARY: E:\FR\FM\20APN1.SGM 20APN1

Agencies

[Federal Register Volume 80, Number 75 (Monday, April 20, 2015)]
[Notices]
[Pages 21743-21744]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-08957]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-N-1037]


Pilot Program for Center for Devices and Radiological Health 
Electronic Submission for Home Use Device Labeling

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) Center for Devices and 
Radiological Health (CDRH) is announcing the availability of a CDRH 
electronic submissions Pilot Program database to house labeling for 
home use devices. Participation in the pilot is open to applicants who 
label their device(s) for home use. Participation in the pilot project 
is voluntary. Participants will be asked to navigate through the 
electronic submissions system and practice submitting labels and 
package inserts. The pilot project is intended to provide industry and 
CDRH staff the opportunity to evaluate the submissions process and 
system and to receive comments from industry participants.

DATES: FDA will accept applications for participation in the voluntary 
electronic submissions CDRH Home Use Device Labeling Pilot Program from 
May 1, 2015, through May 31, 2015. See the ``Participation'' section 
for instructions on how to submit a request to participate. The pilot 
project will occur July 1, 2015, through December 31, 2015.

FOR FURTHER INFORMATION CONTACT: Mary Weick-Brady, Center for Devices 
and Radiological Health, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 66 Rm. 5426, Silver Spring MD 20993, 301-796-
6089, Mary.Brady@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

    CDRH is responsible for ensuring that medical devices are safe and 
effective when used for their intended purpose. Risks are inherent in 
all CDRH-regulated medical devices, and the Center plays a critical 
role in preventing injuries and deaths related to product use. CDRH 
minimizes risk through regulation, enforcement, and education. Risk 
minimization is accomplished, in part, through clear communication on 
the benefits and risks of the medical devices regulated by the Center, 
including communications by CDRH, product manufacturers, and product 
distributors. These communications include medical device labeling 
produced by manufacturers and distributors.
    Medical device labeling provides safety information, instructions 
for use, and/or other necessary information to the user. This labeling 
can be essential for home-use devices, which are much more likely to be 
used by lay users, who frequently have not been trained to use such 
medical devices and who are especially reliant on the instructions for 
use and other information provided by the device label and package 
insert. When used in an environment where a healthcare professional is 
not available to provide supervision and assistance, these devices can 
present unique concerns and challenges. When a home-use device is used 
over a period of years, it becomes increasingly more likely that it may 
be separated from its original labeling or that its original labeling 
will not include current safety information or instructions for use. In 
contrast with use in professional healthcare settings, a patient or 
caregiver using a home-use device in a setting without professional 
oversight may not have extensive experience in the use of a device and 
may not have ready access to the original packaging or to alternative 
sources of information about a device.
    Home-use devices have significant public health importance to 
patients, caregivers, and healthcare professionals. Therefore, it is 
necessary to ensure that users are able to access necessary information 
for use, including safety information and instructions for use. 
Although many manufacturers have Internet sites that provide 
information concerning the devices they currently market, those sites 
typically focus on newer products and often do not provide any 
information on devices that they no longer actively market. Web sites 
also vary considerably in the types of information provided and may 
lack important details concerning their devices. Although some 
manufacturers'

[[Page 21744]]

Web sites provide some labeling, FDA believes that most do not provide 
the label and package insert for all of their home-use devices listed 
with FDA.

II. CDRH Home Use Device Labeling Pilot

    CDRH is developing an electronic submissions database, accessible 
to the public through FDA's Web site, of labels and package inserts for 
listed home-use devices. This database would fill an important gap in 
the information available to patients, caregivers, and the healthcare 
community concerning home-use devices. The database would allow both 
broad searches to identify legally marketed home-use devices that may 
fill a particular need and focused searches to obtain information 
concerning the use of a specific home-use device.
    This electronic submissions database will be evaluated for 
usability through the CDRH Home Use Device Labeling Pilot Project. This 
pilot project will proceed for 6 months. Participation in the pilot is 
open to applicants who label their device(s) for home use. Participants 
will be asked to navigate through the electronic submissions system and 
practice submitting labels and package inserts. The pilot project is 
intended to provide industry and CDRH staff the opportunity to evaluate 
the submissions process and system and to receive comments from 
industry participants. Comments received during the pilot project will 
be used to evaluate the usability of the database. FDA will not review 
the content of any labeling submitted to the pilot database for a 
regulatory purpose. The submitted labeling and the database will only 
be available to pilot participants.

A. Participation

    Volunteers interested in participating in the pilot project should 
contact pilot staff by email at Mary.Brady@fda.hhs.gov. The following 
information should be included in the request: Contact name, contact 
phone number, and contact email address. FDA will contact interested 
applicants to discuss the pilot project. FDA is seeking a limited 
number of participants (no more than nine) to participate in this pilot 
project.

B. Procedures

    By following a series of prompts and instructions, pilot 
participants will submit a PDF version of their device labeling to the 
pilot database. The content of the submissions will not be reviewed by 
FDA for any regulatory purpose, nor will the pilot database be 
available to the public during this pilot project. During the pilot, 
CDRH staff will be available to answer any questions or concerns that 
may arise. Pilot project participants will be asked to comment on and 
discuss their experiences with the pilot submissions process. Their 
comments and discussions will assist CDRH in its development of this 
electronic submissions database.

III. Duration of the Home Use Device Labeling Pilot

    FDA intends to accept requests for participation in the Home Use 
Device Labeling Pilot from May 1, 2015, through May 31, 2015. The pilot 
will proceed for 6 months, from July 1, 2015, through December 31, 
2015. This pilot program may be extended as resources and needs allow.

IV. Paperwork Reduction Act of 1995

    This notice refers to previously approved collections of 
information found in FDA regulations. These collections of information 
are subject to review by the Office of Management and Budget (OMB) 
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The 
collections of information in 21 CFR parts 801 and 809 have been 
approved under OMB control number 0910-0485.

V. Comments

    Interested persons may submit electronic comments regarding the 
Home Use Device Labeling Pilot to https://www.regulations.gov or written 
comments to the Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. It is 
only necessary to send one set of comments. Identify comments with the 
docket number found in brackets in the heading of this document. 
Received comments may be seen in the Division of Dockets Management 
between 9 a.m. and 4 p.m., Monday through Friday and will be posted to 
the docket at https://www.regulations.gov.

    Dated: April 14, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-08957 Filed 4-17-15; 8:45 am]
 BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.